.png)
.png)
Rinri Therapeutics announces new Chair as it approaches first clinical trial
Rinri Therapeutics is pleased to announce the appointment of David Hipkiss as its new Independent Chair. This strategic move comes at a pivotal time as the company prepares to initiate first-in-human trials for its lead asset, Rincell-1.
Harnessing the power of innovation: How the Innovation Map can help your life science company thrive
In this blog, Sam Cruickshank, Programme Manager at BIA, discusses the pivotal role of the recently updated 2024 BIA Innovation Map in empowering life science entrepreneurs to navigate the complexities of the start-up landscape and unlock their ventures' full potential.
Jim Faulkner, Nicole Mather and Carolyn Porter join the Cell and Gene Therapy Catapult as Non-Executive Directors
London, United Kingdom, 29 April 2024: The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, has appointed three new Non-Executive Directors to its board: Jim Faulkner; Nicole Mather; and Carolyn Porter.
Abzena launches EpiScreen® 2.0, a next-generation immunogenicity tool for de-risking the development of complex biologics
Abzena has announced the launch of its enhanced hashtag#bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical hashtag#immunogenicity in protein, antibody, and gene therapy therapeutics.
RNID shine a spotlight on the hearing therapeutics landscape
In this blog, Melissa Hayman, Hearing Therapeutics Manager at RNID, BIA’s charity partner of the year introduces a blog series to be published over the coming months which will examine the hearing therapeutics landscape.
Continuity and change: Labour’s life science strategy
Herbie Lambden, Senior Policy and Public Affairs Executive at the BIA, provides a rundown of the BIA Committee Summit, which took place in Westminster on 21 February.
CEO Update - 22 April 2024
The UK's engineering biology scene was out in force at a Number 10 Downing Street reception last week. It was great to celebrate the developments in our community network together with ministers and investors.
Step up and create more inclusive workplaces within the biotech sector
In last year’s Diversity and Inclusion in UK Biotech survey conducted by the BIA, hearing loss emerged as one of the most prevalent disabilities. With Deaf Awareness Week 2024 (6-12 May) fast approaching, the BIA has teamed up with its charity partner, RNID, to offer valuable resources and initiatives for creating more inclusive workplaces across the biotech sector.
University of Oxford spin-out revealed as winner of ‘Golden Ticket’ programme for planetary health innovations
University of Oxford spin-out HydRegen has been revealed as the winner of a programme designed to recognise innovations in planetary health created by Pioneer Group in partnership with CPI.
Investing in life science – learnings from the first round of investments from Discovery Park Ventures
Launched in May 2022 by thriving life science community Discovery Park, Discovery Park Ventures (DPV) is an investment fund that invests in ambitious and growing life sciences companies, driving disruptive innovation and catalysing economic growth. Initially a £1 million fund, DPV has now expanded to £3 million.